
Swedish drugmaker Meda spurns Mylan takeover approach
STOCKHOLM (Reuters) - Swedish generic drugmaker Meda AB rejected a takeover approach by U.S. rival Mylan Inc to create a combined company worth around $24 billion. The generic drugs sector...
Home > Reviews









